CT1500 Phase 1 Study

CT1500 Phase 1 Study CT1500 Phase 1 Study Circadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marks move to a clinical stage company • First subject dosed for Phase I study• CT-1500 being developed to treat Non-24 Sleep-Wake...

Circadian Therapeutics and Arquimea Collaboration

Circadian Therapeutics and Arquimea Collaboration Circadian Therapeutics and ARQUIMEA sign a collaboration agreement for the development of casein kinase 1 inhibitors for the treatment of diseases affecting the nervous system Co-development of molecules as an...